See article | More media ...
the need | Nexvax2 | our technology | clinical trial | references
Nexvax2 is Nexpep’s lead vaccine candidate, comprised of a mixture of the most commonly recognised gluten peptides in HLA-DQ2-associated coeliac disease.
Nexvax2 has successfully completed pre-clinical testing and has commenced its first clinical trial in April 2009, which is being conducted by Nucleus Network (http://www.nucleusnetwork.com.au) Centre for Clinical Studies (CCS) at the Alfred Hospital in Melbourne, Australia. Please visit http://clinicaltrials.gov for more information about the trial.